Malignant Solid Neoplasm Clinical Trials

184 recruitingLast updated: June 17, 2026

There are 184 actively recruiting malignant solid neoplasm clinical trials across 14 countries. Studies span Not Applicable, Phase 1, Phase 2, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Rochester, Minnesota, United States, Jacksonville, Florida, United States. Updated daily from ClinicalTrials.gov.


Malignant Solid Neoplasm Trials at a Glance

184 actively recruiting trials for malignant solid neoplasm are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Not Applicable with 55 trials, with the heaviest enrollment activity in Houston, Rochester, and Jacksonville. Lead sponsors running malignant solid neoplasm studies include Mayo Clinic, M.D. Anderson Cancer Center, and National Cancer Institute (NCI).

Browse malignant solid neoplasm trials by phase

Treatments under study

About Malignant Solid Neoplasm Clinical Trials

Looking for clinical trials for Malignant Solid Neoplasm? There are currently 106 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Solid Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Solid Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 184 trials

Recruiting
Phase 1Phase 2

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Hematopoietic and Lymphatic System NeoplasmMetastatic Malignant Solid NeoplasmStage IV Colorectal Cancer AJCC v8+4 more
National Cancer Institute (NCI)42 enrolled23 locationsNCT05691491
Recruiting
Phase 3

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors

Malignant Solid NeoplasmMetastatic Malignant Neoplasm in the Brain
Mayo Clinic140 enrolled4 locationsNCT03750227
Recruiting
Phase 1

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
National Cancer Institute (NCI)43 enrolled23 locationsNCT05687110
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 1

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled2 locationsNCT07137416
Recruiting

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Breast CarcinomaEsophageal CarcinomaHead and Neck Carcinoma+6 more
M.D. Anderson Cancer Center5,000 enrolled1 locationNCT00991094
Recruiting
Phase 4

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hepatocellular CarcinomaMetastatic Lung Non-Small Cell Carcinoma+18 more
OHSU Knight Cancer Institute160 enrolled1 locationNCT07405086
Recruiting
Phase 1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+5 more
National Cancer Institute (NCI)45 enrolled7 locationsNCT05372640
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 2

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Malignant Solid NeoplasmMalignant Female Reproductive System NeoplasmRecurrent Malignant Solid Neoplasm+1 more
National Cancer Institute (NCI)70 enrolled187 locationsNCT06126276
Recruiting
Not Applicable

The Vanguard Study: Testing a New Way to Screen for Cancer

Breast CarcinomaOvarian CarcinomaBladder Carcinoma+8 more
National Cancer Institute (NCI)24,000 enrolled37 locationsNCT06995898
Recruiting
Early Phase 1

Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm
M.D. Anderson Cancer Center30 enrolled1 locationNCT06184321
Recruiting
Phase 2

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Metastatic Malignant Solid NeoplasmMetastatic Bladder Urothelial CarcinomaMTAP Deletion+1 more
Northwestern University64 enrolled2 locationsNCT06630416
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)66 enrolled6 locationsNCT05687136
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmMetastatic Colorectal Carcinoma+2 more
National Cancer Institute (NCI)30 enrolled22 locationsNCT05803382
Recruiting
Phase 2

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
National Cancer Institute (NCI)115 enrolled1 locationNCT03907475
Recruiting
Phase 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520
Recruiting
Not Applicable

Increasing Knowledge and Interest in Cancer Clinical Trials

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm
Hayley Thompson384 enrolled1 locationNCT06501040
Recruiting
Not Applicable

Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases

Malignant Brain NeoplasmMalignant Solid NeoplasmProstate Carcinoma+2 more
Mayo Clinic147 enrolled1 locationNCT06788886
Recruiting
Not Applicable

Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial

Malignant Solid NeoplasmHematopoietic and Lymphoid System Neoplasm
Ohio State University Comprehensive Cancer Center208 enrolled1 locationNCT06314672